PhotoPharmics expands Parkinson’s Trial into further US states
Ella Day | August 14, 2025 | News story | Research and Development | Neurology, PhotoPharmics, clinical trial, neurodegenerative disorders
US-based PhotoPharmics, has expanded enrollment in its Light for PD clinical trial beyond its original 300 participants, opening new sites in Illinois, Florida and Arizona. These states were chosen due to their higher populations of retirees and people living with Parkinson’s disease.
The Light for PD study is assessing the safety and effectiveness of Celeste, an FDA-designated non-invasive light therapy. The device intends to improve both motor and non-motor symptoms of Parkinson’s, building on research on circadian science and the potential benefits of light therapy for sleep, mood, motor function and quality of life.
Kent Savage, CEO of PhotoPharmics, said: “We are eager to establish Celeste’s safety and efficacy in a geographically diverse population.”
Participants use the PhotoPharmics device daily at home while continuing their existing Parkinson’s medications. The therapy delivers specific wavelengths of light to the eyes to help restore circadian rhythms and improve brain function, potentially addressing symptoms such as daytime sleepiness, mood disturbances and reduced alertness.
Dan Adams, chief scientific officer at PhotoPharmics, added: “This trial isn’t just testing a device – it’s testing a new way of thinking about Parkinson’s care: safe, non-invasive and rooted in the body’s natural biology.”
PhotoPharmics is a medical device company developing therapies for neurodegenerative disorders using specialised light solutions. Its therapeutics are used to regulate circadian rhythms for seasonal affective disorder, sleep disorders, anxiety and depression.
Ella Day
14/8/25
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
